1 We have characterized the human smooth muscle endothelin converting enzyme (ECE) present in the media of the endothelium-denuded human umbilical vein preparation. 2 Endothelin-1 (ET-1) and ET-2 were potent constrictors of umbilical vein with EC 50 values of 9.2 nM and 29.6 nM, respectively. ET-1 was at least 30 times more potent than ET-3 suggesting the presence of constrictor ET A receptors. Little or no response was obtained to the ET B -selective agonist sarafotoxin 6c. These data suggest that endothelin-mediated vasoconstriction is via ET A receptors in this preparation. 4 Big ET-1 (EC 50 =42.7 nM) and big ET-2 (1-38) (EC 50 =99.0 nM) were less potent than ET-1 and ET-2, respectively. Big ET-2 (1-38) was more potent than its isoform big ET-2 (1-37) with concentration ± response curves to big ET-2 (1-37) incomplete at 300 nM. No response was obtained to big ET-3 at concentrations up to 700 nM. The C-terminal fragments, big ET-1 (22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38) and big ET-2 (22-38) were inactive. 5 Responses to ET-1 were unaected by either the neutral endopeptidase (NEP) inhibitor thiorphan (10 75 M) or by the dual NEP/ECE inhibitor phosphoramidon (10 75 M). Big ET-1 was also unaected by thiorphan but antagonized in a concentration-dependent manner by phosphoramidon (10 75 M and 10
Introduction
The dual endothelin converting enzyme (ECE) and neutral endopeptidase (NEP, neprolysin) inhibitor phosphoramidon, when infused into the human forearm, elicits a vasodilator response, whereas administration of the NEP inhibitor thiorphan results in vasoconstriction (Webb, 1995) . This observation provided compelling evidence that the endogenous production of endothelin contributes signi®cantly to the physiological maintenance of human vascular tone. Over-expression of endothelin is implicated in the development and progression of several cardiovascular diseases (for review see Huggins et al., 1993) . Considerable interest has been focused on the potential of endothelin antagonists as therapeutic agents (Tamirisa et al., 1995; Doherty, 1996) , resulting in the development of a large number of selective compounds, some of which are currently being evaluated for clinical ecacy. Alternatively, limiting the unwanted eects of endothelin in disease may be achieved more precisely by restricting its production.
The endothelin-1 (ET-1) peptide is cleaved from its precursor, big ET-1, by the action of one or more ECEs. ECE activity is blocked by phosphoramidon which is also an effective inhibitor of NEP. However, ECE and NEP can be distinguished by use of thiorphan, which is ineective against ECE but a potent inhibitor of NEP (see Turner & Murphy, 1996) . Two distinct ECEs have so far been cloned and sequenced. ECE-1, ®rst described in bovine adrenal cortex (Xu et al., 1994) , exists in two isoforms. In man (Schmidt et al., 1994; Shimada et al., 1995; Valdenaire et al., 1995; Yorimitsu et al., 1995) , as in other species (Ikura et al., 1994; Schmidt et al., 1994; Shimada et al., 1994; 1995) , these isoforms dier in the N-terminal sequence and are generated by alternative splicing of the same gene product. A second enzyme, ECE-2, possesses approximately 60% sequence homology with ECE-1 but differs markedly in its pH optimum (Emoto & Yanagisawa, 1995) . Evidence now unequivocally points to ECE being a membrane-bound zinc metalloprotease Ohnaka et al., 1992; Schmidt et al., 1994; Xu et al., 1994) belonging to the same family as NEP and the Kell blood group proteins.
In sections of human vascular tissues immunoreactive endothelin and big ET are localized to endothelial cells (Howard et al., 1992; Marciniak et al., 1992; Davenport et al., 1996; Plumpton et al., 1996) , with little evidence for the presence of these peptides in smooth muscle cells. ET-1 is the principle isoform that is released by human endothelial cells. As it is coreleased with big ET-1 in vitro (Plumpton et al., 1994; Ashby et al., 1995) this suggests that conversion of big ET-1 to ET-1 occurs, at least in part, intracellularly. This is supported by studies showing that ECE-1 is localized to the membranes of some intracellular organelles, particularly the Golgi apparatus (Gui et al., 1993; Xu et al., 1994) . However, the rapid conversion of exogenous big ET-1 to ET-1 both in vitro and in vivo also suggests a role for ECE as an ecto-enzyme. Indeed the presence of ECE-1 on the endothelial cell surface has been suggested by several groups (for example Harrison et al., 1993; Barnes et al., 1995; Takahashi et al., 1995) .
What remains unclear is whether ECE is also present in the vascular smooth muscle cells underlying the endothelium. Functional experiments in isolated vascular preparations do suggest that conversion of exogenously applied big ET-1 is unaected by the removal of the endothelium (Fukuroda et al., 1990; Hisaki et al., 1993; Mombouli et al., 1993) , implying the presence of a smooth muscle enzyme. However, this functional data does contrast with the apparent lack of immunoreactive ECE observed in smooth muscle cells , although we have recently identi®ed immunoreactive ECE in the foetal smooth muscle cells of the human umbilical vein. The physiological role of this putative smooth muscle ECE remains to be determined. One possibility is that this enzyme is responsible for the local conversion of big ET-1, which is released from the endothelial cells, and of big ET-2 (1-37) , big ET-2 (1-38) and big ET-3 which have been detected in human plasma (Matsumoto et al., 1994) .
We have therefore functionally characterized the ECE present in human umbilical vein vascular smooth muscle and determined its sensitivity to thiorphan and phosphoramidon. We have made use of the endothelium-denuded human umbilical vein preparation, since vasoconstriction in this blood vessel is suggested to be mediated mainly through the ET B receptor (Bogoni et al., 1996) . All three endothelin isoforms are equipotent at the ET B receptor and therefore this preparation should allow us to determine the substrate speci®city of the enzyme. To con®rm that conversion had taken place and that the big ETs do not themselves possess signi®cant constrictor activity, we have analysed the bathing medium for the presence of mature endothelin by use of a selective radioimmunoassay (RIA). Preliminary results have been presented to the British Pharmacological Society (Maguire et al., 1997).
Methods

Tissue collection
Umbilical cords were obtained following normal and caesarean deliveries and kept refrigerated in sterile phosphate buffered saline (PBS) until required, typically with 8 ± 12 h. For autoradiographical experiments blocks of whole cord, 2 ± 3 cm in length, were snap frozen in liquid nitrogen and stored at 7708C. For immunocytochemistry and in vitro experiments cords were cut into 4 mm lengths from which the umbilical vein was dissected.
Immunocytochemistry
For functional experiments rings of umbilical vein were denuded of their endothelium by gently rubbing the luminal surface with the rounded tip of blunt metal forceps. Removal of the endothelial cell layer was con®rmed by the absence of staining with rabbit antiserum to human von Willebrand factor as previously described (Davenport et al., 1996) .
Autoradiography
The endothelin receptor subtypes present on the smooth muscle cells of umbilical vein were visualized by use of previously published methods (Davenport et al., 1988) . Brie¯y, consecutive 10 mm sections of umbilical cord (n=6) were thaw mounted onto gelatine coated slides and pre-incubated in HEPES buer (50 mM HEPES containing 5 mM MgCl 2 and bovine serum albumin (BSA), 0.3% w/v, pH 7.4) for 15 min at room temperature (238C). The sections were incubated for a further two hours with the same buer to which had been added either 0.1 nM [ 
In vitro pharmacology
Rings (4 mm) of endothelium-denuded human umbilical vein were transferred to 5 ml tissue baths (Linton Instrumentation, Diss, Norfolk, U.K.) containing modi®ed Krebs solution, maintained at 378C and continuously oxygenated with 95% O 2 /5% CO 2 . The blood vessel rings were set up between two L-shaped wires for isometric force measurements (F30 isometric force transducers, Hugo Sachs Elektronik, March-Hugstetten, Germany) and allowed to equilibrate for 60 min. Responses were elicited to 50 mM KCl at increasing levels of resting tension until no additional increase in the magnitude of the KCl response was obtained. The preparations were left for a further 30 min until a stable baseline was established. Cumulative concentration-response curves were constructed to ET-1, ET-2, ET-3, sarafotoxin 6c (S6c), big ET-1, big ET-2 (1-37) , big ET-2 (1-38) , big ET-3 and the C-terminal fragments big ET-1 (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) and big ET-2 (22-38) (10 710 ± 10 76 M). Only one agonist was tested on each vein ring. Concentration-response curves to ET-1 and big ET-1 were repeated in the presence of thiorphan (10 75 M) and phosphoramidon (10 75 M and 10 74 M) which were added to the bathing medium 20 min before the agonists. Experiments were terminated by the addition of 50 mM KCl to the bath to determine the maximum contractile response for each preparation. Agonist reponses were subsequently expressed as a percentage of this maximum. Values of EC 50 (concentration producing 50% of the maximum response) were obtained from the graphs of log 10 agonist concentration plotted against response (% of KCl). At the end of the experiments the bath contents were collected and stored at 7208C for the subsequent measurement of endothelin-like immunoreactivity (ET-IR) by radioimmunoassay (RIA).
Radioimmunoassay
The method used is essentially that previously described and employed an antiserum directed against the C-terminal sequence that is common to the three mature endothelin peptides. This assay detects all three isoforms equally well, but does not cross-react with the big endothelins or truncated forms of the endothelins. Dilutions of ET-1 standards and bath content samples were made in assay buer (50 mM sodium phosphate, 0.25% BSA, 0.01% Tween 20, 0.05% sodium azide, pH 7.4) and 100 ml aliquots were incubated for 16 ± 24 h at 48C with an equal volume of the antiserum (®nal dilution 1 : 30,000). The tracer ([ , big ET-3, big ET-1 (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) , big , sarafotoxin 6c (S6c) and phosphoramidon were purchased from the Peptide Institute (Osaka, Japan) and thiorphan was from Sigma Chemical Co. (St. Louis, MO., U.S.A.). Stock solutions (10 72 ± 10 74 M) were prepared in 0.1% acetic acid and stored at 7208C. Unlabelled PD151242 (N-[hexahydro-1-azepinyl) ]Ac-ET-1 (6-21) ) was synthesized by solid phase t-Boc chemistry. Stock solutions of PD151242 (10 72 M) were prepared in dimethylsulphoxide and those of BQ3020 (10 74 M) was prepared in 0.01 M ammonia, also stored at 7208C. Immunocytochemistry reagents were from Dako A/S (Denmark). All other reagents were from Sigma Chemical Co. (Poole, Dorset) or BDH (Lutterworth, Leics., U.K.) and were of analar grade or better.
Modi®ed Krebs solution had the following composition (mM): NaCl 90, KCl 5, MgSO 4 . 7H 2 O 0.5, Na 2 HPO 4 1, NaHCO 3 45, CaCl 2 2.25, glucose 10, Na pyruvate 5, fumaric acid 5 and L-glutamic acid 5.
Results
Endothelium removal procedure
In sections of intact umbilical vein (n=3) it was possible to visualize individual endothelial cells stained with the von Willebrand factor antiserum. These cells were absent in sections of vein (n=3) whose luminal surface had been rubbed verifying the success of the procedure (data not shown).
Autoradiography
High speci®c binding was observed in the media (smooth muscle layer) of umbilical vein (n=6) to the non-selective ligand [ 
In vitro pharmacology
The majority of the isolated umbilical vein preparations exhibited spontaneous, phasic contractile activity. This appeared immediately after they were placed in the tissue bath or developed following the normalization procedure. The remaining preparations were quiescent throughout the experiments. In all tissues the responses to the agonists were determined as the increase in baseline tension upon which these phasic contractions may be superimposed.
ET-1 and ET-2 potently contracted isolated umbilical vein with EC 50 values of 9.2 nM (6.0 ± 14.0, n=17) and 29.6 nM (16.5 ± 53.2, n=10) (geometric mean with 95% con®dence intervals), respectively. The response of umbilical vein (n=11) to ET-3 was much more variable. ET-3 was less potent than either ET-1 or ET-2 with the concentration ± response curves either incomplete at 700 nM, or in a minority of vessels no response was obtained even at this concentration (Figure 2 ). Vessels which contracted poorly following addition of high concentrations of ET-3 showed normal responsiveness to 50 mM KCl, with a mean maximum contraction of 9.9+1.3 g
ET-1
ET-2 ET-3 Potency values are the geometric mean with 95% con®dence intervals in parentheses; n values are the number of umbilical cords from which veins were obtained.
weight. This was not signi®cantly dierent from the maximum contractile response observed with KCl following either the ET-1 (7.9+0.9 g weight) or the ET-2 (7.7+1.0 g weight) concentration ± response curves (P40.05, Student's one-tailed t test). The ET B agonist S6c (10 711 ± 10 77 M) was inactive in six of the eight veins in which it was tested. In the two veins in which responses were obtained, contractions were obtained to low concentrations of S6c, with EC 50 values of less than 1 nM. However, the maximum responses were considerably less (550%) than those obtained to ET-1 in the same experiment (Figure 2) . The maximum KCl contraction following addition of S6c was 7.9+1.2 g weight, again comparable to that for the other agonists (Table 1) .
Big ET-1 was approximately ®ve times less potent than ET-1 with an EC 50 value of 42.7 nM (26.6 ± 68.7 nM, n=23). Big ET-1 was at least twice as potent as big (EC 50 99.0 nM (61.4 ± 160 nM, n=11)), which was more potent again than its isoform big ET-2 (1-37) (n=9). The peak responses to big ET-1 and big ET-2 (1-38) were not dierent from that to ET-1, the concentration ± response curve to big ET-2 (1-37) was incomplete at 700 nM (Figure 3) . Big ET-3 (n=5) did not elicit any response at concentrations up to 700 nM. C-terminal fragments, big ET-1 (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) and big were inactive and did not antagonize the contractile responses to ET-1.
The concentration ± response curve of ET-1 was unaected by the presence of the NEP inhibitor thiorphan (10 75 M) or by the dual NEP/ECE inhibitor phosphoramidon (10 75 M) (Figure 4a , Table 2 ). Although there was no alteration of the big ET-1 curve following the addition of thiorphan (10 75 M) there was a small shift of the big ET-1 curve in the presence of phosphoramidon (10 75 M) (Figure 4b ). This eect of phosphoramidon was concentration-dependent with a further degree of shift obtained with the higher concentration (10
of the inhibitor (Figure 4b , Table 2 ). 10 ± 40 nM. Lower levels of ET-IR were also present in all bath samples to which the big endothelin peptides had been added (Table 3) . ET-IR was not detected when big ET-1 was incubated without tissue, or when tissue was incubated without big ET-1 (data not shown). Therefore big ET-1 was not reverting to ET-1 spontaneously, nor was ET-1 being produced in measurable amounts by the umbilical vein rings in vitro.
Discussion
Inhibition of the ECE activity in vascular endothelial cells may prove to be an eective therapeutic strategy to limit the unwanted eects of over-production of endothelins in disease. However, endothelial cells produce exclusively ET-1 (Plumpton et al., 1996) and therefore the other two isoforms, ET-2 and ET-3, must be processed from their precursors at other sites. Big ET-2 and big ET-3 are present in signi®cant amounts in the plasma and, as there is little evidence for ECE activity in human blood (Watanabe et al., 1991) , it is likely that they are converted to their mature forms at their target organs. One possibility is that circulating big ET-2 and big ET-3, together with big ET-1 that is co-released with ET-1 from the endothelium, are converted to the active peptides by an ECE present on vascular smooth muscle cells. The existence of such a smooth muscle ECE has previously been suggested. Homogenates of bovine carotid artery converted big ET-1 to ET-1 in a pH-sensitive manner; activity at neutral pH was phosphoramidon-sensitive and predominantly membrane bound (Hioki et al., 1991) . A more recent study also localized ECE-1 to the extracellular surface of cultured vascular smooth muscle cells (Emoto et al., 1996) and described the conversion of exogenuously applied big ET-1.
In the present study, we have investigated the nature of the smooth muscle ECE in human umbilical vein preparations. Bogoni and colleagues (1996) have recently published functional data which suggests that the endothelin peptides mediate their constrictor eects mainly via the ET B receptor. However, we found that ET-1 and ET-2 were much more potent than ET-3 suggesting the presence of constrictor ET A receptors. This was con®rmed by the lack of signi®cant response obtained with the selective ET B agonist sarafotoxin 6c. These data were also supported by the autoradiographic visualization of endothelin receptor subtypes by use of receptor-speci®c radioligands that showed the predominance of the ET A receptor in the vascular smooth muscle layer. It is dicult to explain the discrepancies between these two investigations. The only striking dierence in experimental method was the use of a vein strip preparation by Bogoni and colleagues (1996) and a ring preparation in the present study. The use of agonists and antagonists that have better selectivity for human endothelin receptor subtypes may be required for this anomaly to be resolved.
Big ET-1 was a less potent constrictor than ET-1, of umbilical vein, although the dierence in potency of the two peptides was much less than that found for other blood vessels including human coronary arteries (Howard et al., 1992; Bax et al., 1994) . If the EC 50 values obtained for the two peptides are compared then big ET-1 appears to have 20% of the activity of ET-1. This suggests that either big ET-1 itself has anity for endothelin receptors or it must be converted to ET-1 for its biological activity. To exclude the possibility that big ET-1 possesses intrinsic biological activity and to con®rm that conversion to ET-1 must occur for its biological activity, we used RIA to show the presence of ET-IR in the bathing medium following addition of big ET-1. Therefore our data obtained in vitro agree with results determined in the human forearm in vivo, where the haemodynamic eects of infused big ET-1 are due, at least in part, to its conversion to ET-1 .
The ECE present in this particular human smooth muscle preparation appears to convert all of the big endothelin precursors. Thus big ET-2 (1-37) and big ET-2 (1-38) had some vasoconstrictor activity, though less than big ET-1, and given the low potency of ET-3 it was unsurprising that big ET-3 was inactive at the concentrations tested. However, in each case we detected similar levels of ET-IR in the bathing medium. It is Potency values are the geometric mean with 95% con®dence intervals in parentheses; n values are the number of umbilical cords from which veins were obtained. Values are the mean+s.e.mean; n values are the number of experiments from which bath contents were analysed.
not possible to determine the absolute substrate speci®city of the enzyme in the present study, as the amounts of ET-IR re¯ect only free peptide concentration and not receptor bound and non-speci®cally bound peptide. The enzyme responsible for this conversion diers from NEP since the vasoconstrictor response of big ET-1 was blocked by phosphoramidon but unaected by the NEP inhibitor thiorphan. These data also suggest that the smooth muscle ECE is dierent from the endothelial cell ECE which does not convert big ET-2 or big ET-3 as eciently as big ET-1 (Schmidt et al., 1994; Xu et al., 1994; Shimada et al., 1995) .
Therefore, we have demonstrated the presence of a phosphoramidon-sensitive ECE present on human vascular smooth muscle cells that does not distinguish between the endothelin peptide precursors. The precise subcellular localization of this enzyme and its physiological relevance remains to be determined.
